Ratings by Canaccord (Sumant Kulkami)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/9/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Buy (N/A) |
34.61 (36.74) |
6.15% | Details | |
| 9/3/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 8/18/2026 | Annovis Bio Inc. | ANVS | Maintain | Buy (Buy) |
|
Details | ||
| 8/13/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 8/4/2026 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 7/28/2026 | MapLight Therapeutics | MPLT | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2026 | MapLight Therapeutics | MPLT | Maintain | Buy (N/A) |
|
Details | ||
| 7/16/2026 | AtaiBeckley Inc | ATAI | Downgrade | Hold (Buy) |
5.36 (7.35) |
37.13% | Details | |
| 7/7/2026 | AtaiBeckley Inc | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 6/29/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 4/20/2026 | AtaiBeckley Inc | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2026 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2026 | MapLight Therapeutics | MPLT | New Coverage | Buy (N/A) |
17.02 (7.70) |
-54.76% | Details | |
| 2/3/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 1/27/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 1/5/2026 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 10/22/2025 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2025 | Annovis Bio Inc. | ANVS | Maintain | Buy (Buy) |
|
Details | ||
| 9/24/2025 | atai Life Sciences N.V | ATAI | Maintain | Buy (Buy) |
|
Details | ||
| 7/28/2025 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 7/2/2025 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 6/26/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 6/9/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (Buy) |
|
Details | ||
| 5/15/2025 | Annovis Bio Inc. | ANVS | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Annovis Bio Inc. | ANVS | Maintain | Buy (Buy) |
|
Details | ||
| 5/7/2024 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2024 | Annovis Bio Inc. | ANVS | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2024 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 12/29/2023 | Annovis Bio Inc. | ANVS | New Coverage | Buy (N/A) |
19.56 (0.99) |
-94.94% | Details | |
| 11/6/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 7/27/2023 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 6/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 4/26/2023 | Stoke Therapeutics | STOK | New Coverage | Buy (N/A) |
8.11 (24.17) |
198.03% | Details | |
| 3/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2022 | Acadia Pharmaceuticals | ACAD | Upgrade | Buy (Hold) |
22.27 (19.12) |
-14.14% | Details | |
| 12/22/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Hold (N/A) |
|
Details | ||
| 8/6/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Hold (N/A) |
|
Details | ||
| 7/13/2021 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
19.00 (5.36) |
-71.79% | Details | |
| 5/12/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Hold (N/A) |
|
Details | ||
| 4/6/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Hold (Buy) |
21.18 (19.12) |
-9.73% | Details | |
| 3/9/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details |
